ISDS Case Map
intellectual property
A European Parliament Committee rejected the Anti-Counterfeiting Trade Agreement (ACTA) yesterday despite pro-business lobbying by Trade Commissioner Karel De Gucht, who insisted that Parliament should not decide before the European Court of Justice gives its opinion. A final vote in the full Parliament is expected on 4 July.
The Office of the United States Trade Representative (USTR) yesterday released an interim report with the European Union on ways to expand transatlantic trade and investment. But apparently this would not include trying to bridge differences on intellectual property rights.
Former Canadian Prime Minister Brian Mulroney is wading into the high-stakes debate over patent protection in the free trade talks with Europe, and he's clearly taking sides.
Colombia's Constitutional Court will hear two suits challenging the new copyright law under the country's free trade agreement with the United States, local media reported Tuesday.
The provincial premiers have undertaken a letter-writing campaign to demand compensation from the federal government for any increase in drug costs that might results from a free-trade agreement with Europe.
The UN's top agency for HIV-AIDS has warned that million of lives could be at risk, if intellectual property and other trade agreements impede access to treatment.
New comparative analysis shows that TPP contains a plethora of TRIPS-plus provisions as well as ACTA-plus and Chile FTA-plus provisions.
Smoking is bad for our health.
Smoking is detrimental to our economic well-being - smoking-related conditions and diseases cost the health service in this country millions and millions of dollars each year. But moves to reduce or stop smoking in this country could cost us just as much if not more.
Chile's top trade official Rodrigo Contreras makes clear that intellectual property issues are at the forefront of his mind when he questions whether Chile should continue in the TPP.
There’s a debate raging over Canada’s intellectual property regime. If one side’s right, Canada stands to pay $2.8 billion more every year in drug costs while it undermines its generic-drug manufacturing sector.
